Switching of COVID-19 Vaccines: a solution for the problems?

Switching of COVID-19 Vaccines: a solution for the problems? - SWITCH

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-000701-24-NL

Enrollment

600

Registered

2021-03-22

Start date

2021-03-31

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Care Workers of the Erasmus Medical Centre will be vaccinated with Covid-19 vaccinations. They will either receive two the same vaccines or two different after which immune response will be measured

Interventions

Trade Name: Comirnaty concentraat voor dispersie voor injectie Pharmaceutical Form: Dispersion for injection Trade Name: COVID-19 vaccine Moderna, dispersie voor injectie Pharmaceutical Form: Dispers

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All HCW who work in the health care facility with at least one confirmed SARS CoV-2 infected patient receiving care and who have symptoms associated with SARS CoV-2. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 600 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0

Exclusion criteria

Exclusion criteria: 1. HCW younger than 18 2. HCW that are pregnant or have a wish to become pregnant within 6 months 3. All regular contra-indications of the vaccines will be applied

Design outcomes

Primary

Measure	Time frame
Main Objective: to measure the immune response against SARS-CoV-2 after two different vaccinations in Health Care Workers (HCW) (intervention group). This will be compared with HCW that will receive two boosts from the same vaccines (control group).;Secondary Objective: 1. To assess adverse events after SARS-CoV-2 vaccination. 2. To evaluate development of antibody and cellular response after 1st vaccination 3. To assess durability of the antibody response 4. To analyze the SARS-CoV-2-specific T and B cell response after vaccination ;Primary end point(s): Detection of immunity against SARS-CoV-2;Timepoint(s) of evaluation of this end point: At baseline and after SARS-CoV-2 vaccination, which will be performed according to standard of care, blood will be drawn at in 5 different time points, i.e. baseline (before 1st vaccination), at day of 2nd vaccination, and 28 days, and 6 and 12 months after 2nd vaccination.	—

Measure

Time frame

Main Objective: to measure the immune response against SARS-CoV-2 after two different vaccinations in Health Care Workers (HCW) (intervention group). This will be compared with HCW that will receive two boosts from the same vaccines (control group).;Secondary Objective: 1. To assess adverse events after SARS-CoV-2 vaccination. 2. To evaluate development of antibody and cellular response after 1st vaccination 3. To assess durability of the antibody response 4. To analyze the SARS-CoV-2-specific T and B cell response after vaccination ;Primary end point(s): Detection of immunity against SARS-CoV-2;Timepoint(s) of evaluation of this end point: At baseline and after SARS-CoV-2 vaccination, which will be performed according to standard of care, blood will be drawn at in 5 different time points, i.e. baseline (before 1st vaccination), at day of 2nd vaccination, and 28 days, and 6 and 12 months after 2nd vaccination.

—

Secondary

Measure	Time frame
Secondary end point(s): NA;Timepoint(s) of evaluation of this end point: NA	—

Countries

Netherlands

Contacts

Public ContactHugo van der Kuy

Erasmus MC

h.vanderkuy@erasmusmc.nl0031628586702

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026